Summary
64 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: ¥57.7B against ¥4.23B.
- The share price is below the Bulios Fair Price.
- Out of every 100 JPY of revenue, 12 JPY is left as net profit.
- Earnings per share grew by 13% a year over the last 3 years.
What to watch
- It earns only 4.7 JPY a year on every 100 JPY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.2 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 1.1% a year over 5 years. Over the last 3 years it grew by 7.3% a year. Earnings per share grew by 13% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 JPY of revenue goes
- Cost of sales 42 JPY
- Research and development 23 JPY
- Sales and administration 24 JPY
- Taxes and other -0.4 JPY
- Net profit 12 JPY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 JPY
Out of every 100 JPY of revenue, 12 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 4.63%
- Paid out of profit
- 70%
- Raised in a row
- 1 year
You receive $1.20 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.